Adverse event profile of regimen containing BMS-790052 was consistent with that of treatment with PEG-Interferon alfa and ribavirin alone (PRINCETON, N.J., March 31, 2011) – Bristol-Myers Squibb ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback